Genetic markers that predict treatment response in advanced prostate cancer
Official title: Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11173720 · Data updated 2026-11-12
This project looks at whether tumor and inherited DNA changes can show which men with advanced prostate cancer are most likely to benefit from targeted drugs and immunotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 14, 2001 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $212,659 |
| NIH project number | 5P50CA092629-24 |
| Project ID | NIH-11173720 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with locally advanced or metastatic prostate cancer, especially those willing to provide tumor tissue and a blood sample or who have prior tumor/germline sequencing, are the ideal candidates.
✕Less likely to help
People without prostate cancer, men with low-risk disease unlikely to need systemic therapy, or those unable/unwilling to give samples or access medical records would not directly benefit.
What this research studies
If you have advanced prostate cancer, this project would collect your tumor tissue and a blood sample to look at tumor and inherited DNA changes that might affect treatment response. Researchers at Memorial Sloan Kettering will build a large database linking genomic data with treatments and outcomes to find patterns tied to progression or benefit from PARP inhibitors and immunotherapy. The team focuses on DNA repair genes such as BRCA2 and on microsatellite instability, while also searching for other genomic signals that predict outcomes. Your medical records and samples would be analyzed to match specific genetic changes to real-world treatment results.
Why it matters
Potential benefit: If successful, the work could help personalize therapy by identifying which patients are most likely to respond to PARP inhibitors or immune checkpoint inhibitors.
How similar studies have gone: Approvals of PARP inhibitors and pembrolizumab for genomically defined prostate cancers show this approach can work for some patients, but predicting who will benefit remains imperfect.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Solit, David B. — Sloan-Kettering Inst Can Research
- Study coordinator: Solit, David B.
Related research
Other NIH-funded projects on the same topics.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.